Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
94.43
+1.30 (+1.40%)
4:37:08 PM EDT: $94.78 +0.35 (+0.37%)
Products

Merck And Ridgeback Announce New Data For Investigational Molnupiravir From Phase 3 Move-Out Study

Published: 06/07/2022 11:14 GMT
Merck & Co Inc (MRK) - Merck and Ridgeback Announce New Data for Investigational Lagevrio™ (molnupiravir) From Phase 3 Move-out Study.
Merck - Based on Prespecified Endpoints, Lower Proportion of Participants Treated With Lagevrio Had Acute Care Visit Versus Those Who Received Placebo.
Merck - Based on a Post Hoc Analysis, Fewer Required Respiratory Interventions (including Invasive Mechanical Ventilation).